Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Radius Health

After 30 years of research, pill developed at Duke for breast cancer approved for use

After six years of painful injections, Stephanie Walker has had enough.

Tribune News Service

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Merger Arbitrage Mondays - Zendesk To Be Acquired By Permira and Hellman & Friedman

Merger Arbitrage Mondays - Zendesk To Be Acquired By Permira and Hellman & Friedman

Editor's Note: Starting next month, we will be rolling the Merger Arbitrage Mondays series into our paid subscription services, Inside Arbitrage Plus and Inside Arbitrage Premium. The more affordable Plus service focuses on content including a monthly special situations newsletter, a model portfolio and mid-month updates. The Premium service includes both…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

4 Analysts Have This to Say About Radius Health

Analysts have provided the following ratings for Radius Health (NASDAQ:RDUS) within the last quarter:

Bone Health Focused Radius Health Goes Private In $890M Deal

Radius Health Inc (NASDAQ:RDUS) will be acquired by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million, including the assumption of debt and assuming full payment of the CVR (Contingent Value Right). Gurnet Point and Patient Square will pay $10.00 per share in cash plus a…

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022

Radius Health's Return On Capital Employed Insights

Radius Health (NASDAQ:RDUS) brought in sales totaling $43.16 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 17.27%, resulting in a loss of $18.28 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: Radius Health Q1 Earnings

Recap: Radius Health Q1 Earnings

Radius Health (NASDAQ:RDUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

How To Attend Radius Health Q1 2022 Earnings Conference Call

How To Attend Radius Health Q1 2022 Earnings Conference Call

Radius Health (NASDAQ:RDUS) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Radius Health (RDUS) Conference Call Follow this link to access the live webcast.

Radius Health: A Biotech Stock Worth Buying Now?

Radius Health: A Biotech Stock Worth Buying Now?

With continuing investments in research and development to extend human lifespans and improve the quality of life, the biotech industry looks poised for growth. RDUS is a fundamentally strong player in this space. So, let’s discuss if it is wise to bet on the name amid the current market volatility.…

1

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Wall Street Journal

Spirit Airlines

Food and Drug Administration

B of A Securities

JetBlue Airways

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Sickle Cell Disease

Places

388,966 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play